Recombinant
Recombinant Anti-Tropomyosin 2 antibody [EPR12846] - C-terminal (ab180176)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR12846] to Tropomyosin 2 - C-terminal
- Suitable for: IP, WB
- Reacts with: Mouse, Rat, Human
Overview
-
Product name
Anti-Tropomyosin 2 antibody [EPR12846] - C-terminal
See all Tropomyosin 2 primary antibodies -
Description
Rabbit monoclonal [EPR12846] to Tropomyosin 2 - C-terminal -
Host species
Rabbit -
Tested applications
Suitable for: IP, WBmore details
Unsuitable for: Flow Cyt,ICC/IF or IHC-P -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide within Human Tropomyosin 2 aa 200 to the C-terminus (internal sequence) (Cysteine residue). The exact sequence is proprietary.
Database link: P07951 -
Positive control
- HeLa, HT-1080, fetal muscle and heart lysates, Human fetal muscle lysate.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading... -
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
EPR12846 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
Our Abpromise guarantee covers the use of ab180176 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| IP | 1/10 - 1/100. | |
| WB | 1/1000 - 1/5000. Predicted molecular weight: 33 kDa. |
Application notes
Is unsuitable for Flow Cyt,ICC/IF or IHC-P.
Target
-
Function
Binds to actin filaments in muscle and non-muscle cells. Plays a central role, in association with the troponin complex, in the calcium dependent regulation of vertebrate striated muscle contraction. Smooth muscle contraction is regulated by interaction with caldesmon. In non-muscle cells is implicated in stabilizing cytoskeleton actin filaments. The non-muscle isoform may have a role in agonist-mediated receptor internalization. -
Tissue specificity
Present in primary breast cancer tissue, absent from normal breast tissue. -
Involvement in disease
Nemaline myopathy 4 (NEM4) [MIM:609285]: A form of nemaline myopathy. Nemaline myopathies are muscular disorders characterized by muscle weakness of varying severity and onset, and abnormal thread-or rod-like structures in muscle fibers on histologic examination. Nemaline myopathy type 4 presents from infancy to childhood with hypotonia and moderate-to-severe proximal weakness with minimal or no progression. Major motor milestones are delayed but independent ambulation is usually achieved, although a wheelchair may be needed in later life. Note=The disease is caused by mutations affecting the gene represented in this entry.
Arthrogryposis, distal, 1A (DA1A) [MIM:108120]: A form of distal arthrogryposis, a disease characterized by congenital joint contractures that mainly involve two or more distal parts of the limbs, in the absence of a primary neurological or muscle disease. Distal arthrogryposis type 1 is characterized largely by camptodactyly and clubfoot. Hypoplasia and/or absence of some interphalangeal creases is common. The shoulders and hips are less frequently affected. Note=The disease is caused by mutations affecting the gene represented in this entry. -
Sequence similarities
Belongs to the tropomyosin family. -
Domain
The molecule is in a coiled coil structure that is formed by 2 polypeptide chains. The sequence exhibits a prominent seven-residues periodicity. -
Post-translational
modificationsPhosphorylated on Ser-61 by PIK3CG. Phosphorylation on Ser-61 is required for ADRB2 internalization. -
Cellular localization
Cytoplasm > cytoskeleton. - Information by UniProt
-
Database links
- Entrez Gene: 7169 Human
- Entrez Gene: 22004 Mouse
- Entrez Gene: 500450 Rat
- Omim: 190990 Human
- SwissProt: P07951 Human
- SwissProt: P58774 Mouse
- SwissProt: P58775 Rat
- Unigene: 300772 Human
see all -
Alternative names
- Alpha tropomyosin antibody
- AMCD1 antibody
- Arthrogryposis multiplex congenital distal type 1 antibody
see all
Images
-
![Immunoprecipitation - Anti-Tropomyosin 2 antibody [EPR12846] - C-terminal (ab180176)](https://www.abcam.com/ps/products/180/ab180176/Images/ab180176-208858-anti-tropomyosin-2-antibody-epr12846-c-terminal-immunoprecipitation.jpg)
Immunoprecipitation - Anti-Tropomyosin 2 antibody [EPR12846] - C-terminal (ab180176)Western blot analysis on immunoprecipitation pellet from Human fetal muscle lysate labeling Tropomyosin 2 using ab180176 at 1/10.
-
![Western blot - Anti-Tropomyosin 2 antibody [EPR12846] - C-terminal (ab180176)](https://www.abcam.com/ps/products/180/ab180176/Images/ab180176-208856-anti-tropomyosin-2-antibody-epr12846-c-terminal-western-blot.jpg)
Western blot - Anti-Tropomyosin 2 antibody [EPR12846] - C-terminal (ab180176)All lanes : Anti-Tropomyosin 2 antibody [EPR12846] - C-terminal (ab180176) at 1/1000 dilution
Lane 1 : Fetal heart lysate
Lane 2 : HeLa cell lysate
Lane 3 : HT-1080 cell lysate
Lane 4 : Fetal muscle lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Standard HRP labeled goat anti-rabbit at 1/2000 dilution
Developed using the ECL technique.
Predicted band size: 33 kDa
Datasheets and documents
References
ab180176 has been referenced in 1 publication.
- Gao M & Si X Rapamycin ameliorates psoriasis by regulating the expression and methylation levels of tropomyosin via ERK1/2 and mTOR pathways in vitro and in vivo. Exp Dermatol 27:1112-1119 (2018). PubMed: 30019485
